Alnylam Pharmaceuticals said that it has expanded its management team to include two new vice presidents and a CSO.
Kenneth Koblan, who has been named CSO, previously held various positions within Merck Research Laboratories, most recently vice president and site head of Rahway Basic Research. He holds a PhD in biochemistry from Johns Hopkins University.
Alnylam's previous CSO, John Schmidt, left the company in August of 2009.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
